Advertisement

Empirische Befunde zum Einsatz von Antidepressiva zur Therapie von Minussymptomen

  • J. Tegeler

Zusammenfassung

Schon kurz nach Einführung der Antidepressiva wurden diese Substanzen nicht nur bei depressiven Patienten, sondern auch bei Schizophrenen eingesetzt. So beschrieb Kuhn (1957) einen günstigen affektiv distanzierenden und sedativen Effekt des Imipramins bei nichterregten Schizophrenen. Pöldinger (1963) sah bei chronisch katatonen Schizophrenen unter Amitriptylin eine therapeutische Wirksamkeit und bezeichnete Amitriptylin als Thymoleptikum mit neuroleptischer Wirkungskomponente. In den späten 50er und 60er Jahren berichteten verschiedene Autoren über einen günstigen therapeutischen Effekt von Imipramin, Nortriptylin und Amitriptylin bei Schizophrenien mit Minussymptomen (Feldman 1959; Arnold et al. 1960; Haider 1966). Gross u. Huber (1980) empfahlen die Verabreichung von Desipramin bei depressivapathischen Syndromen im Rahmen schizophrener Erkrankungen. In den letzten Jahren wurden zahlreiche kontrollierte Studien durchgeführt, in denen die Wirksamkeit der Antidepressiva und Monoaminooxydasehemmer als Monotherapie oder in Kombination mit Neuroleptika geprüft wurde.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alexander PE, Kammen DP van, Bunney ER jr (1979) Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 136: 283–287.PubMedGoogle Scholar
  2. Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reüability. Arch Gen Psychiatry 36: 784–788.CrossRefGoogle Scholar
  3. Angst J (1961) A clinical analysis of the effects of tofranil in depression. Psychopharmacologia 2: 381–407.PubMedCrossRefGoogle Scholar
  4. Arnold OH, Hift ST, Hoff H (1960) Die Stellung der psychotropen Drogen im Gesamtbehandlungsplan der Psychiatrie. Wien Med Wochenschr 11: 238–245.Google Scholar
  5. Avery D, Winokur G (1977) The efficacy of electroconvulsive therapy and antidepressants in depression. Biol Psychiatry 12: 507–523.PubMedGoogle Scholar
  6. Barnes TRE, Curson DA, Liddle PF, Patel M (1989) The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154: 486–491.PubMedCrossRefGoogle Scholar
  7. Bennett IF, Cohen D, Starer E (1954) Isoniazid in treatment of the chronic schizophrenic patient. Arch Neurol Psychiatry 71: 54–65.Google Scholar
  8. Berner P, Lenz G (1986) Definitions of schizoaffective psychosis: mutual concordance and relationship to schizophrenia and affective disorder. In: Marneros A, Tsuang MT (eds) Schizoaffective psychoses. Springer, Berlin Heidelberg New York Tokyo.Google Scholar
  9. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D (1987) Neuroleptic responsitivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549–1556.PubMedGoogle Scholar
  10. Brenner R, Shopsin B (1980) The use of monoamine-oxidase inhibitors in schizophrenia. Biol Psychiatry 15: 633–647.PubMedGoogle Scholar
  11. Brockington IF, Kendell RE, Kellett JM, Curry SH, Wainwright S (1978) Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 133: 162–168.PubMedCrossRefGoogle Scholar
  12. Brockington IF, Kendell RE, Wainwright S (1980) Depressed patients with schizophrenic or paranoid symptoms. Psych Medicine 10: 665–675.CrossRefGoogle Scholar
  13. Carman JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42: 124–128.PubMedGoogle Scholar
  14. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452.PubMedGoogle Scholar
  15. Chouinard G, Annable L, Serrano M (1975) Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 32: 1295–1307.PubMedCrossRefGoogle Scholar
  16. Dufresne RL, Kass DJ, Becker RE (1988) Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia. Drug Dev Res 12: 259–266.CrossRefGoogle Scholar
  17. Feldman PE (1959) The treatment of anergic schizophrenia with imipramine. J Clin Exp Psychopathol 20: 235–242.Google Scholar
  18. Freyhan FA (1957) Psychomotilität extrapyramidaler Syndrome und Wirkungsweisen neuroleptischer Therapie. Nervenarzt 28: 504–509.PubMedGoogle Scholar
  19. Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J (1989) Determinanten schizophrener Residualsymptomatik. Vortrag DGPN-Kongreß Erlangen.Google Scholar
  20. Glatzel J, Seyfeddinipur N (1981) Die sogenannte Symptomprovokation bei schizophrenen Psychosen. In: Huber G (Hrsg) Die Bedeutung der Neuroleptika für die Behandlung schizophrener Erkrankungen. Das Ärztliche Gespräch, Bd 31. pmi-pharm and medical information, Frankfurt/M..Google Scholar
  21. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456.PubMedGoogle Scholar
  22. Goodnick P, Meltzer H (1984) Treatment of schizoaffective disorders. Schizophr Bull 10: 30–48.PubMedGoogle Scholar
  23. Greenblatt M, Grosser GH, Wechsler H (1962) A comparative study of selected antidepressant medications and ECT. Am J Psychiatry 119: 144–153.PubMedGoogle Scholar
  24. Gross G, Huber G (1980) Depressive Syndrome im Verlauf von Schizophrenien. Fortschr Neurol Psychiat 48: 438–446.CrossRefGoogle Scholar
  25. Guertin WH, Regnier WO, Good RW (1960) Response of chronic schizophrenics to a monoamine oxidase inhibitor. Dis Nerv Syst 21: 330–332.PubMedGoogle Scholar
  26. Haider I (1966) A comparative trial of nortriptyline and amitriptyline in chronic schizophrenia. Br J Clin Pract 20: 416–417.PubMedGoogle Scholar
  27. Hanlon TE, Nussbaum K, Wittig B (1964) The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients. J New Drugs 4: 52–60.Google Scholar
  28. Hedberg DL, Houck JH, Glueck BC (1971) Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 127: 1141–1146.PubMedGoogle Scholar
  29. Heinrich K (1960) Die gezielte Symptomprovokation mit monoaminooxydasehemmenden Substanzen in Diagnostik und Therapie schizophrener Psychosen. Nervenarzt 31: 507–572.PubMedGoogle Scholar
  30. Hirschkowitz J, Casper R, Garver DL, Chang S (1980) Lithium response in good prognosis schizophrenia. Am J Psychiatry 137: 916–920.Google Scholar
  31. Hordern A, Holt NF, Burt CG, Gordon WF (1963) Amitriptyline in depressive states. Br J Psychiatry 109: 815–825.PubMedCrossRefGoogle Scholar
  32. Hoshino A, Cease EA (1958) Iproniazid phosphate in the treatment of the chronic hospitalized schizophrenic. Am J Psychiatry 114: 1111.PubMedGoogle Scholar
  33. Johnson DAW (1981) Studies of depressive symptoms in schizophrenia. Br J Psychiatry 139: 89–101.PubMedCrossRefGoogle Scholar
  34. Johnstone EC, Frith CD, Crow TJ, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet I: 848–851.CrossRefGoogle Scholar
  35. Kamman GR, Freeman JG, Lucero RJ (1953) The effect of 1-isonicothynl 2-isopropyl hydrazide on the behavior of long-term mental patients. J Nerv Ment Dis 118: 391–407.PubMedCrossRefGoogle Scholar
  36. Kammen DP van, Alexander PE, Bunney WE (1980) Lithium-treatment in postpsychotic depression. Br J Psychiatry 136: 479–485.PubMedCrossRefGoogle Scholar
  37. Kane JM, Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment? Br J Psychiatry 155 (Suppl 7): 115–118.Google Scholar
  38. Keefe RSE, Mohs RC, Losonczy MF et al. (1987) Characteristics of very poor outcome schizophrenia. Am J Psychiatry 144: 889–895.PubMedGoogle Scholar
  39. Kendell RE (1986) The relationship of schizoaffective illnesses to schizophrenic and affective disorders. In: Marneros A, Tsuang MT (eds) Schizoaffective psychoses. Springer, Berlin Heidelberg New York Tokyo.Google Scholar
  40. Klein DF (1968) Importance of psychiatric diagnosis in prediction of clinical drug effect. Psychopharmacology 13: 359–386.CrossRefGoogle Scholar
  41. Klein DF, Fink M (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatry 119: 432–438.PubMedGoogle Scholar
  42. Klein DF, Oaks G (1967) Importance of psychiatric diagnoses in prediction of clinical drug effects. Arch Gen Psychiatry 16: 118–126.PubMedCrossRefGoogle Scholar
  43. Klieser E (1988) Experimentelle Untersuchung zur Differentialindikation von Neuroleptika und Thymoleptika. Habilitationsschrift, Düsseldorf.Google Scholar
  44. Kramer MC, Vogel WH, DiJohnson C et al. (1989) Antidepressants in “depressed” schizophrenic inpatients. Arch Gen Psychiatry 46: 922–928.PubMedCrossRefGoogle Scholar
  45. Kuhn R (1957) Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr 87: 1135–1140.PubMedGoogle Scholar
  46. Kurland AA, Nagaraju A (1981) Viloxazine and the depressed schizophrenic: methodological issues. J Clin Pharmacol 21: 37–41.PubMedGoogle Scholar
  47. Leuthold CA, Bradshaw FJ, Arndt GW (1961) Behavioral evaluation of imipramine and nialamide in regressed schizophrenic patients with depressive features. Am J Psychiatry 118: 354–355.PubMedGoogle Scholar
  48. McKenna PJ, Lund CE, Mortimer AM (1989) Negative symptoms: relationship to other schizophrenic symptomclasses. Br J Psychiatry 155 (Suppl 7): 104–107.Google Scholar
  49. Meltzer HY, Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (eds) Clinical psychopharmacology in psychiatry. Psychopharmacol Series 7. Springer, Berlin Heidelberg New York Tokyo.Google Scholar
  50. Möller HJ (1987) Konsequenzen aus der klinischen Pharmakologie für die nosologische und syndromatologische Klassifikation funktioneller psychischer Störungen. In: Simhandl C, Berner P, Luccioni H (Hrsg) Klassifikationsprobleme in der Psychiatrie. Medizinisch-Pharmazeutische Verlagsgesellschaft, Purkersdorf.Google Scholar
  51. Möller HJ, Morin C (1989) Behandlung schizodepressiver Syndrome mit Antidepressiva. In: Marneros A (Hrsg) Schizoaffektive Psychosen — Diagnose, Therapie und Prophylaxe. Springer, Berlin Heidelberg New York Tokyo.Google Scholar
  52. Nedopil N, Rüther E (1983) Psychopharmakatherapie bei schizoaffektiven Psychosen. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York.Google Scholar
  53. Overall JE, Hollister LE, Meyer F (1964) Imipramine and thioridazine in depressed and schizophrenic patients. JAMA 189: 605–608.PubMedCrossRefGoogle Scholar
  54. Pietzcker A, Gaebel W, Köpcke W et al. (1986) A german multi-center study on the neuroleptic longterm therapy of schizophrenic patients. Pharmacopsychiatry 19: 161–166.CrossRefGoogle Scholar
  55. Pishkin V (1972) Concept identification and psychophysiological parameters in depressed schizophrenic as functions of imipramine and nialamide. J Clin Psychol 28: 335–339.PubMedCrossRefGoogle Scholar
  56. Pöldinger W (1963) Laroxyl (Amitriptylin), ein Thymoleptikum mit neuroleptischer Wirkungskomponente. Nervenarzt 34: 80–84.Google Scholar
  57. Pollack M, Klein DF, Willner A (1965) Imipramine — induced behavioral disorganisation in schizophrenic patients. Rec Adv Biol Psychiatry 7: 53–61.Google Scholar
  58. Prosser ES, Csernansky JG, Kaplan J, Thieman S, Becker TJ, Hollister LE (1987) Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 175: 100–105.PubMedCrossRefGoogle Scholar
  59. Prusoff BA, Williams DH, Weisman MM, Astrachan BA (1979) Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry 36: 569–575.PubMedCrossRefGoogle Scholar
  60. Simpson GM, Amin M, Angus JWS (1972) Role of antidepressants and neuroleptics in the treatment of depression. Arch Gen Psychiatry 27: 337–347.PubMedCrossRefGoogle Scholar
  61. Singh AN, Saxena B, Nelson HL (1978) A controlled study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr Ther Res 23: 485–499.Google Scholar
  62. Siris SG, Kammen DP van, Docherty JP (1978) Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 35: 1368–1377.PubMedCrossRefGoogle Scholar
  63. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB (1987) Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 44: 533–539.PubMedCrossRefGoogle Scholar
  64. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988) Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145: 1532–1537.PubMedGoogle Scholar
  65. Siris SG, Cutler J, Owen K, Mason S, Gingerich S, Lang MP (1989) Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression. Am J Psychiatry 146: 1495–1497.PubMedGoogle Scholar
  66. Small JG, Kellams JJ, Milstein V, Moore J (1975) A placebo controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132: 1315–1317.PubMedGoogle Scholar
  67. Spiker DG (1981) Schizoaffective disease and atypical psychosis. Psychopharmacol Bull 17: 75–78.PubMedGoogle Scholar
  68. Taylor MA (1986) The validity of schizoaffective disorders: treatment and prevention studies. In: Marneros A, Tsuang MT (eds) Schizoaffective psychoses. Springer, Berlin Heidelberg New York Tokyo.Google Scholar
  69. Waehrens J, Gerlach J (1980) Antidepressant drugs in anergic schizophrenia: a double-blind cross-over study with maprotiline and placebo. Acta Psychiatr Scand 61: 438–444.PubMedCrossRefGoogle Scholar
  70. Weinberger TR, Bigelow LB, Kleinman JE (1980) Cerebral ventricular enlargement and poor response to treatment. Arch Gen Psychiatry 37: 11–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. Tegeler

There are no affiliations available

Personalised recommendations